Design Therapeutics
DSGN· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +52.0% in FY2025
Pratik Shah, Ph.D. is the CEO of Design Therapeutics and was paid $3.5M in FY2025 (Dec), up 349%.
Pay$100 in the stock at the end of FY21 → $170
Executives3
See all- 1Pratik Shah, Ph.D.President, Chief Executive Officer and ChairpersonFY2025
- 2Sean Jeffries, Ph.D.Chief Operating OfficerFY2025
- 3Chris M. Storgard, M.D.Chief Medical OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allDesign Therapeutics paid its 2 named executives $5.4M in total in FY2025 (Dec). CEO Pratik Shah, Ph.D. was paid $3.5M of that.
| Name | |||
|---|---|---|---|
| Pratik Shah, Ph.D.President, Chief Executive Officer and Chairperson | Not disclosed | ||
| Sean Jeffries, Ph.D.Chief Operating Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Design Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Simeon George, M.D.Lead independent director · 4 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- John SchmidDirector · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Arsani William, M.D.Director · 3 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Deepa PrasadDirector · 3 yr on the boardIndependentAudit—Paid as an executive
- Heather Berger, Ph.D.Director · 3 yr on the boardIndependentAudit, Research and Development—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 9, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 24, 2025 | FY2024 |
| Annual report | 10-K | Mar 10, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Mar 19, 2024 | FY2023 |